Use of Sertoli cell transplants to provide local immunoprotection for tissue grafts

Expert Opinion on Biological Therapy

Volumn 4, Issue 6, 2004, Pages 813-825

  Halberstadt, Craig ^a   Emerich, Dwaine F ^b   Gores, Paul ^a  

^a CAROLINAS MEDICAL CENTER   (United States)

^b LCT BioPharma   (United States)

Author keywords

Diabetes; Islets; Neurological disorder; Parkinson's disease; Sertoli cells; Transplant; Xenotransplantation

Indexed keywords

ADOPTIVE IMMUNOTHERAPY; ALLOGRAFT; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; BRAIN; CELL TRANSPLANTATION; GRAFT SURVIVAL; IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PARKINSON DISEASE; RAT; REVIEW; SECRETORY CELL; SERTOLI CELL; TISSUE GRAFT; TISSUE REGENERATION; XENOTRANSPLANTATION;

ANIMALS; CELL TRANSPLANTATION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; MALE; MODELS, BIOLOGICAL; NERVOUS SYSTEM DISEASES; PARKINSON DISEASE; RATS; SERTOLI CELLS; SWINE; TESTIS; TIME FACTORS; TISSUE TRANSPLANTATION; TRANSPLANTATION, HETEROLOGOUS; TRANSPLANTS;

ANIMALIA;

EID: 3042638699     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.4.6.813     Document Type: Review

References (109)

1. SHAPIRO AM, LAKEY JR, RYAN EA et al.: Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N. Engl. J. Med. (2000) 343(4):230-238. Demonstration of 100% successful human allogeneic islet transplantation for the treatment of type I diabetes.
2. COLTON CK: Implantable biohybrid artificial organs. Cell Transplant. (1995) 4(4):415-436. Excellent review of cell encapsulation.
3. BYRNE GW, MCCURRY KR, MARTIN MJ et al.: Transgenic pigs expressing human CD59 and decay-accelerating factor produce an intrinsic barrier to complement-mediated damage. Transplantation (1997) 63(1):149-155.
4. COSTA C, ZHAO L, BURTON WV et al.: Expression of the human alpha1,2-fucosyltransferase in transgenic pigs modifies the cell surface carbohydrate phenotype and confers resistance to human serum-mediated cytolysis. FASEB J. (1999) 13(13):1762-1773.
5. VAN DEN BOGAERDE J, WHITE DJ: Xenogeneic transplantation. Br. Med. Bull. (1997) 53(4):904-920.
6. AO Z, KORBUTT GS, WARNOCK GL et al.: Microencapsulation improves canine islet survival in vivo. Transplant. Proc. (1995) 27(6):3349.
7. GARFINKEL MR, HARLAND RC, OPARA EC: Optimization of the microencapsulated islet for transplantation. J. Surg. Res. (1998) 76(1):7-10.
8. LACY PE: Pancreatic islet cell transplant. Mt. Sinai J. Med. (1994) 61(1):23-31.
9. LANZA RP, BEYER AM, STARUK JE, CHICK WL: Biohybrid artificial pancreas. Long-term function of discordant islet xenografts in streptozotocin diabetic rats. Transplantation (1993) 56(5):1067-1072.
10. LIM F: Microencapsulation of living mammalian cells. Adv. Biotechnol. Processes (1988) 7:185-197.
11. HILL RS, CRUISE GM, HAGER SR et al.: Immunoisolation of adult porcine islets for the treatment of diabetes mellitus. The use of photopolymerizable polyethylene glycol in the conformal coating of mass-isolated porcine islets. Ann. NY Acad. Sci. (1997) 831:332-343.
12. RAMSOONDAR JJ, MACHATY Z, COSTA C et al.: Production of alpha 1,3-galactosyltransferase-knockout cloned pigs expressing human alpha 1,2-fucosylosyltransferase. Biol. Reprod. (2003) 69(2):437-445.
13. LAVITRANO M, BACCI ML, FORNI M et al.: Efficient production by sperm-mediated gene transfer of human decay accelerating factor (hDAF) transgenic pigs for xenotransplantation. Proc. Natl. Acad. Sci. USA (2002) 99(22):14230-14235.
14. BARKER CF, BILLINGHAM RE: Immunologically privileged sites. In: Advances in Immunology. Kunkel MG, Dixon FJ (Eds), Academic Press, New York, USA (1977). Excellent historical reference on the transplantation of tissues into privileged sites.
15. SELAWRY H: Islet transplantation to immunoprivileged sites. In: Immunomodulation of Pancreatic Islets. Lanza RP, Chick W (Eds), R.G. Landes Company, Austin, TX, USA (1994):75-86.
16. SELAWRY HP, WHITTINGTON K: Extended allograft survival of islets grafted into intra-abdominally placed testis. Diabetes (1984) 33(4):405-406. Original demonstration of islet allografts surviving in the testes and reversing diabetes.
17. RUSSELL LD, GRISWOLD MD: The Sertoli Cell. Russell LD, Griswold MD (Eds), Cache River Press, Clearwater, FL (1993):1-801. Comprehensive reference on Sertoli cell biology.
18. MARGOLIS RN, HOLUP JJ, SELAWRY HP: Effects of intratesticular islet transplantation on hepatic glycogen metabolism in the rat. Diabetes Res. Clin. Pract. (1986) 2(5):291-299.
19. WHITTINGTON KB, SOLOMON SS, LU ZN, SELAWRY HP: Islet allografts in the cryptorchid testes of spontaneously diabetic BB/Wor dp rats: response to glucose, glipizide, and arginine. Endocrinology (1991) 128(6):2671-2677.
20. SELAWRY HP, WHITTINGTON KB, BELLGRAU D: Abdominal intratesticular islet-xenograft survival in rats. Diabetes (1989) 38(Suppl. 1):220-223.
21. SELAWRY H, GABER AO: Intratesticular islet allograft survival in the Rhesus monkey without sustained immunosuppression. Cell Transplant. (2004) (In Press).
22. GORES PF, HAYES DH, COPELAND MJ et al.: Long-term survival of intratesticular porcine islets in nonimmunosuppressed beagles. Transplantation (2003) 75(5):613-618. Convincing demonstration of xenogeneic islet survival in a large animal model.
23. SELAWRY HP, WHITTINGTON KB: Prolonged intratesticular islet allograft survival is not dependent on local steroidogenesis. Horm. Metab. Res. (1988) 20(9):562-565.
24. CAMERON DF, WHITTINGTON K, SCHULTZ RE, SELAWRY HP: Successful islet/abdominal testis transplantation does not require Leydig cells. Transplantation (1990) 50(4):649-653.
25. SELAWRY HP, CAMERON DF: Sertoli cell-enriched fractions in successful islet cell transplantation. Cell Transplant. (1993) 2(2):123-129.
26. KORBUTT GS, ELLIOTT JF, RAJOTTE RV: Cotransplantation of allogeneic islets with allogeneic testicular cell aggregates allows long-term graft survival without systemic immunosuppression. Diabetes (1997) 46(2):317-322. First demonstration by another investigator confirming Dr Selawry's allogeneic Sertoli cell and islet transplant results.
27. KORBUTT GS, SUAREZ-PINZON WL, POWER RF, RAJOTTE RV, RABINOVITCH A: Testicular Sertoli cells exert both protective and destructive effects on syngeneic islet grafts in non-obese diabetic mice. Diabetologia (2000) 43(4):474-480.
28. SUAREZ-PINZON W, KORBUTT GS, POWER R et al.: Testicular Sertoli cells protect islet beta-cells from autoimmune destruction in NOD mice by a transforming growth factor-beta1-dependent mechanism. Diabetes (2000) 49(11):1810-1818.
29. WRIGHT JR JR, POHAJDAK B: Cell therapy for diabetes using piscine islet tissue. Cell Transplant. (2001) 10(2):125-143.
30. YANG H, WRIGHT JR JR: Co-encapsulation of Sertoli enriched testicular cell fractions further prolongs fish-to-mouse islet xenograft survival. Transplantation (1999) 67(6):815-820.
31. YANG H, AL-JAZAERI A, WRIGHT JR JR: The immunoprotective effect of Sertoli cells coencapsulated with islet xenografts is not dependent upon Fas ligand expression. Cell Transplant. (2002) 11(8):799-801.
32. KIN T, RAJOTTE RV, DUFOUR JM, KORBUTT GS: Development of an immunoprivileged site to prolong islet allograft survival. Cell Transplant. (2002) 11(6):547-552.
33. CALAFIORE R, LUCA G, CALVITTI M et al.: Cellular support systems for alginate microcapsules containing islets, as composite bioartificial pancreas. Ann. NY Acad. Sci. (2001) 944:240-251.
34. LUCA G, CALVITTI M, NERI LM et al.: Mitogenic effects of rat Sertoli cells on adult homologous islet beta-cells: in vitro and in vivo studies. Transplant. Proc. (2001) 33(1-2):681-682.
35. TAKEDA Y, GOTOH M, DONO K et al.: Acceptance of islet allografts transplanted with Fas ligand expressing testicular allografts. Transplant. Proc. (1999) 31(1-2):624.
36. FREEMAN TB, WIDNER H: Cell Transplantation for Neurological Disorders. Freeman TB, Widner H (Eds), Humana Press, Totowa, NJ, USA (1998).
37. CAMERON DF, OTHBERG AI, BORLONGAN CV et al.: Post-thaw viability and functionality of cryopreserved rat fetal brain cells cocultured with Sertoli cells [see comments]. Cell Transplant. (1997) 6(2):185-189.
38. OTHBERG AI, WILLING AE, CAMERON DF et al.: Trophic effect of porcine Sertoli cells on rat and human ventral mesencephalic cells and hNT neurons in vitro [published erratum appears in Cell Transplant. (1998) 7(5):497]. Cell Transplant. (1998) 7(2):157-164.
39. OTHBERG AI, WILLING AE, CAMERON DF et al.: Trophic effect of porcine Sertoli cells on rat and human ventral mesencephalic cells and hNT neurons in vitro [published erratum appears in Cell Transplant. (1998) 7(5):497]. Cell Transplant. (1998) 7(2):157-164.
40. SANBERG PR, BORLONGAN CV, OTHBERG AI et al.: Testis-derived Sertoli cells have a trophic effect on dopamine neurons and alleviate hemiparkinsonism in rats. Nat. Med. (1997) 3(10):1129-1132.
41. SAPORTA S, CAMERON DF, BORLONGAN CV, SANBERG PR: Survival of rat and porcine Sertoli cell transplants in the rat striatum without cyclosporine-A immunosuppression. Exp. Neurol. (1997) 146(2):299-304.
42. SANBERG PR, BORLONGAN CV, SAPORTA S, CAMERON DF: Testis-derived Sertoli cells survive and provide localized immunoprotection for xenografts in rat brain [see comments]. Nat. Biotechnol. (1996) 14(13):1692-1695. First demonstration that Sertoli cells can survive and enable co-transplantation of discordant cells in the brain.
43. WILLING AE, SUDBERRY JJ, OTHBERG AI et al.: Sertoli cells decrease microglial response and increase engraftment of human hNT neurons in the hemiparkinsonian rat striatum. Brain Res. Bull. (1999) 48(4):441-444.
44. WILLING AE, CAMERON DF, SANBERG PR: Sertoli cell transplants: their use in the treatment of neurodegenerative disease. Mol. Med. Today (1998) 4(11):471-477.
45. BORLONGAN CV, CAMERON DF, SAPORTA S, SANBERG PR: Intracerebral transplantation of testis-derived Sertoli cells promotes functional recovery in female rats with 6-hydroxydopamine-induced hemiparkinsonism. Exp. Neurol. (1997) 148(1):388-392.
46. LIU HW, KUANG YJ, WU JC et al.: Intrastriatal transplantation of Sertoli cells may improve amphetamine-induced rotation and tyrosine hydroxylase immunoreactivity of the striatum in hemiparkinsonian rats. Brain Res. (1999) 838(1-2):227-233.
47. RODRIGUEZ AI, WILLING AE, CAMERON DF, SAPORTA S, SANDBERG PR: Neurobehavioral assessment of transplanted porcine Sertoli cells into the intact rat striatum. Neurotox. Res. (2002) 4(2):103-109.
48. RODRIGUEZ AI, WILLING AE, SAPORTA S, CAMERON DF, SANBERG PR: Effects of Sertoli cell transplants in a 3-nitropropionic acid model of early Huntington's disease: a preliminary study. Neurotox. Res. (2003) 5(6):443-450.
49. HEDGER MP, MEINHARDT A: Cytokines and the immune-testicular axis. J. Reprod. Immunol. (2003) 58(1):1-26. Excellent review on the immunoprivileged environment of the testis.
50. HEDGER MP: Macrophages and the immune responsiveness of the testis. J. Reprod. Immunol. (2002) 57(1-2):19-34.
51. POLLANEN P, VON EULER M, SODER O: Testicular immunoregulatory factors. J. Reprod. Immunol. (1990) 18(1):51-76.
52. FILIPPINI A, RICCIOLI A, PADULA F et al.: Control and impairment of immune privilege in the testis and in semen. Hum. Reprod. Update (2001) 7(5):444-449.
53. STREILEIN JW: Unraveling immune privilege. Science (1995) 270(5239):1158-1159.
54. HEDGER MP: Testicular leukocytes: what are they doing? Rev. Reprod. (1997) 2(1):38-47.
55. TUNG KS, YULE TD, MAHI-BROWN CA, LISTROM MB: Distribution of histopathology and Ia positive cells in actively induced and passively transferred experimental autoimmune orchitis. J. Immunol. (1987) 138(3):752-759.
56. HULEIHEL M, LUNENFELD E, BLINDMAN A, PRINSLOO I, POTASHNIK G: Over expression of interleukin-1alpha, interleukin-1beta and interleukin-1 receptor antagonist in testicular tissues from sexually immature mice as compared to adult mice. Eur. Cytokine Netw. (2003) 14(1):27-33.
57. SODER O, SULTANA T, JONSSON C et al.: The interleukin-1 system in the testis. Andrologia (2000) 32(1):52-55.
58. ZEYSE D, LUNENFELD E, BECK M, PRINSLOO I, HULEIHEL M: Induction of interleukin-1alpha production in murine Sertoli cells by interleukin-1. Biol. Reprod. (2000) 62(5):1291-1296.
59. STEPHAN JP, SYED V, JEGOU B: Regulation of Sertoli cell IL-1 and IL-6 production in vitro. Mol. Cell. Endocrinol. (1997) 134(2):109-118.
60. LEGUE F, GUITTON N, BROUAZIN-JOUSSEAUME V et al.: IL-6 a key cytokine in in vitro and in vivo response of Sertoli cells to external gamma irradiation. Cytokine (2001) 16(6):232-238.
61. HAAGMANS BL, HOOGERBRUGGE JW, THEMMEN AP, TEERDS KJ: Rat testicular germ cells and Sertoli cells release different types of bioactive transforming growth factor beta in vitro. Reprod. Biol. Endocrinol. (2003) 1(1):3.
62. BELLGRAU D, GOLD D, SELAWRY H et al.: A role for CD95 ligand in preventing graft rejection. Nature (1995) 377(6550):630-632. Controversial article proposes that FasL expression by Sertoli cells is the primary agent for conferring immunoprotection of transplanted islets.
63. KOJI T, HISHIKAWA Y, ANDO H, NAKANISHI Y, KOBAYASHI N: Expression of Fas and Fas ligand in normal and ischemia-reperfusion testes: involvement of the Fas system in the induction of germ cell apoptosis in the damaged mouse testis. Biol. Reprod. (2001) 64(3):946-954.
64. MEINHARDT A, BACHER M, O'BRYAN MK et al.: A switch in the cellular localization of macrophage migration inhibitory factor in the rat testis after ethane dimethane sulfonate treatment. J. Cell Sci. (1999) 112(Pt 9):1337-1344.
65. BAILEY RW, DUNKER AK, BROWN CJ, GARNER EC, GRISWOLD MD: Clusterin, a binding protein with a molten globule-like region. Biochemistry (2001) 40(39):11828-11840.
66. DE CESARIS P, FILIPPINI A, CERVELLI C et al.: Immunosuppressive molecules produced by Sertoli cells cultured in vitro: biological effects on lymphocytes. Biochem. Biophys. Res. Commun. (1992) 186(3):1639-1646.
67. SELAWRY HP, KOTB M, HERROD HG, LU ZN: Production of a factor, or factors, suppressing IL-2 production and T cell proliferation by Sertoli cell-enriched preparations. A potential role for islet transplantation in an immunologically privileged site. Transplantation (1991) 52(5):846-850.
68. LEE HO, FERGUSON TA: Biology of FasL. Cytokine Growth Factor Rev. (2003) 14(3-4):325-335.
69. LAN P, ZHAN W, WANG J et al.: Immune privilege induced by cotransplantation of islet and allogeneic testicular cells. Chin. Med. J. (Engl.) (2001) 114(10):1026-1029.
70. ZHAN W, CAI S, WANG J et al.: The effect of FasL expression on pancreatic islet allografts. Chin. Med. J. (Engl.) (2002) 115(7):1006-1009.
71. HSU PN, LIN HH, TU CF et al.: Expression of human Fas ligand on mouse beta islet cells does not induce insulitis but is insufficient to confer immune privilege for islet grafts. J. Biomed. Sci. (2001) 8(3):262-269.
72. KANG SM, SCHNEIDER DB, LIN Z et al.: Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat. Med. (1997) 3(7):738-743. This and [72] contradict the findings from Bellgrau et al. [61] - that FasL is key for immunoprotection. The potential issues with these articles may be that FasL was not regulated in its expression.
73. ALLISON J, GEORGIOU HM, STRASSER A, VAUX DL: Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc. Natl. Acad. Sci. USA (1997) 94(8):3943-3947. See [71].
74. ABDI R, MEANS TK, LUSTER AD: Chemokines in islet allograft rejection. Diabetes Metab. Res. Rev. (2003) 19(3):186-190.
75. MOORE C, HUTSON JC: Physiological relevance of tumor necrosis factor in mediating macrophage-Leydig cell interactions. Endocrinology (1994) 134(1):63-69.
76. MAUDUIT C, BESSET V, CAUSSANEL V, BENAHMED M: Tumor necrosis factor alpha receptor p55 is under hormonal (follicle-stimulating hormone) control in testicular Sertoli cells. Biochem. Biophys. Res. Commun. (1996) 224(3):631-637.
77. RICCIOLI A, FILIPPINI A, DE CESARIS P et al.: Inflammatory mediators increase surface expression of integrin ligands, adhesion to lymphocytes, and secretion of interleukin 6 in mouse Sertoli cells. Proc. Natl. Acad. Sci. USA (1995) 92(13):5808-5812.
78. BELLGRAU D, SELAWRY HP: Cyclosporine-induced tolerance to intratesticular islet xenografts. Transplantation (1990 Oct) 50(4):654-657.
79. DUFOUR JM, HEMENDINGER R, HALBERSTADT CR et al.: Genetically engineered Sertoli cells are able to survive allogeneic transplantation. Gene Ther. (2004) 11(8):694-700. This reference presents the possibility of using animal transgenic Sertoli cells as a means for delivering therapeutic proteins.
80. HEMENDINGER RA, GORES P, BLACKSTEN L, HARLEY V, HALBERSTADT C: Identification of a specific Sertoli cell marker, Sox9, for use in transplantation. Cell Transplant. (2002) 11(6):499-505.
81. DUFOUR JM, GORES P, HEMENDINGER R, EMERICH DF, HALBERSTADT CR: Transgenic Sertoli cells as a vehicle for gene therapy. Cell Transplant. (2004) 13(1):1-6.
82. EMERICH DF, HEMENDINGER R, HALBERSTADT CR: The testicular-derived Sertoli cell: cellular immunoscience to enable transplantation. Cell Transplant. (2003) 12(4):335-349.
83. VALDES-GOMZALAEZ RA, ELLIOTT RB, DORANTES LM et al.: Porcine islet xenografts can survive and function in type 1 diabetic patients in the presence of both pre-existing and elicited anti-pig antibodies. XIX International Congress of the Transplantation Society. Miami, USA (25-30 August 2002).
84. BIRMINGHAM K: Skepticism surrounds diabetes xenograft experiment. Nat. Med. (2002) 8(10):1047.
85. CHECK E: Diabetes trial stirs debate on safety of xenotransplants. Nature (2002) 419(6902):5.
86. CLEMENCEAU B, JEGOU D, MARTIGNAT L, SAI P: Microchimerism and transmission of porcine endogenous retrovirus from a pig cell line or specific pathogen-free pig islets to mouse tissues and human cells during xenografts in nude mice. Diabetelogia (2002) 45(6):914-923.
87. SWITZER WM, MICHLER RE, SHANMUGAM V et al.: Lack of cross-species transmission of porcine endogenous retrovirus infection to nonhuman primate recipients of porcine cells, tissues, or organs. Transplantation (2001) 71(7):959-965.
88. ROSSINI AA, GREINER DL, MORDES JP: Induction of immunologic tolerance for transplantation. Physiol. Rev. (1999) 79(1):99-141.
89. POLLANEN P, VON EULER M, JAHNUKAINEN K et al.: Role of transforming growth factor beta in testicular immunosuppression. J. Reprod. Immunol. (1993) 24(2):123-137.
90. HULEIHEL M, LUNENFELD E: Involvement of intratesticular IL-1 system in the regulation of Sertoli cell functions. Mol. Cell. Endocrinol. (2002) 187(1-2):125-132.
91. PETERSEN C, BOITANI C, FROYSA B, SODER O: Interleukin-1 is a potent growth factor for immature rat Sertoli cells. Mol. Cell. Endocrinol. (2002) 186(1):37-47.
92. DE CESARIS P, STARACE D, RICCIOLI A et al.: Tumor necrosis factor-alpha induces interleukin-6 production and integrin ligand expression by distinct transduction pathways. J. Biol. Chem. (1998) 273(13):7566-7571.
93. JENNE DE, TSCHOPP J: Molecular structure and functional characterization of a human complement cytolysis inhibitor found in blood and seminal plasma: identity to sulfated glycoprotein 2, a constituent of rat testis fluid. Proc. Natl. Acad. Sci. USA (1989) 86(18):7123-7127.
94. BAILEY RW, ARONOW B, HARMONY JA, GRISWOLD MD: Heat shock-initiated apoptosis is accelerated and removal of damaged cells is delayed in the testis of clusterin/ApoJ knock-out mice. Biol. Reprod. (2002) 66(4):1042-1053.
95. VERAJAKORVA E, LAATO M, POLLANEN P: CD 99 and CD 106 (VCAM-1) in human testis. Asian J. Androl. (2002) 4(4):243-248.
96. MARTI HH, RISAU W: Systemic hypoxia changes the organ-specific distribution of vascular endothelial growth factor and its receptors. Proc. Natl. Acad. Sci. USA (1998) 95(26):15809-15814.
97. ERGUN S, KILIC N, FIEDLER W, MUKHOPADHYAY AK: Vascular endothelial growth factor and its receptors in normal human testicular tissue. Mol. Cell. Endocrinol. (1997) 131(1):9-20.
98. ZAKIN MM, BARON B, GUILLOU F: Regulation of the tissue-specific expression of transferrin gene. Dev. Neurosci. (2002) 24(2-3):222-226.
99. SYLVESTER SR, GRISWOLD MD: The testicular iron shuttle: a 'nurse' function of the Sertoli cells. J. Androl. (1994) 15(5):381-385.
100. SKINNER MK, GRISWOLD MD: Sertoli cells synthesize and secrete transferrin-like protein. J. Biol. Chem. (1980) 255(20):9523-9525.
101. SKINNER MK, COSAND WL, GRISWOLD MD: Purification and characterization of testicular transferrin secreted by rat Sertoli cells. Biochem. J. (1984) 218(2):313-320.
102. GNESSI L, EMIDI A, JANNINI EA et al.: Testicular development involves the spatiotemporal control of PDGFs and PDGF receptors gene expression and action. J. Cell Biol. (1995) 131(4):1105-1121.
103. MAGNANTI M, GANDINI O, GIULIANI L et al.: Erythropoietin expression in primary rat Sertoli and peritubular myoid cells. Blood (2001) 98(9):2872-2874.
104. CANIPARI R, GALDIERI M: Retinoid modulation of plasminogen activator production in rat Sertoli cells. Biol. Reprod. (2000) 63(2):544-550.
105. CLARK AM, GARLAND KK, RUSSELL LD: Desert hedgehog (Dhh) gene is required in the mouse testis for formation of adult-type Leydig cells and normal development of peritubular cells and seminiferous tubules. Biol. Reprod. (2000) 63(6):1825-1838.
106. BITGOOD MJ, SHEN L, MCMAHON AP: Sertoli cell signaling by Desert hedgehog regulates the male germline. Curr. Biol. (1996) 6(3):298-304.
107. MULLANEY BP, SKINNER MK: Basic fibroblast growth factor (bFGF) gene expression and protein production during pubertal development of the seminiferous tubule: follicle-stimulating hormone-induced Sertoli cell bFGF expression. Endocrinology (1992) 131(6):2928-2934.
108. RICHARDSON LL, KLEINMAN HK, DYM M: Basement membrane gene expression by Sertoli and peritubular myoid cells in vitro in the rat. Biol. Reprod. (1995) 52(2):320-330.
109. SKINNER MK, FRITZ IB: Structural characterization of proteoglycans produced by testicular peritubular cells and Sertoli cells. J. Biol. Chem. (1985) 260(21):11874-11883.